Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.
The empagliflozin CV benefit was "astounding" and a first for any diabetes drug, but what does it actually mean?
Sodium glucose cotransporter 2 inhibitors act independently of insulin level and so can be used at various stages of type 2 diabetes disease progression. Latest findings, here.
Bariatric surgery is recommended along with oral therapy to help patients with type 2 diabetes control overweight and obesity.
Sodium-glucose linked transporter 2 inhibitors lower renal threshold for glucose transport, cause glycosuria, improved glycemic control, weight loss.